Sanford C. Bernstein Analysts Give Bayer (BAYN) a €115.00 Price Target

Share on StockTwits

Sanford C. Bernstein set a €115.00 ($133.72) price objective on Bayer (FRA:BAYN) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other research firms also recently issued reports on BAYN. Jefferies Financial Group set a €123.00 ($143.02) target price on Bayer and gave the stock a buy rating in a research report on Monday, June 4th. UBS Group set a €130.00 ($151.16) target price on Bayer and gave the stock a buy rating in a research report on Friday, June 1st. Warburg Research set a €118.00 ($137.21) target price on Bayer and gave the stock a neutral rating in a research report on Monday, June 4th. Kepler Capital Markets set a €104.00 ($120.93) target price on Bayer and gave the stock a neutral rating in a research report on Monday, June 4th. Finally, equinet set a €118.00 ($137.21) target price on Bayer and gave the stock a buy rating in a research report on Monday, June 4th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of Buy and an average price target of €104.05 ($120.98).

FRA:BAYN opened at €73.49 ($85.45) on Wednesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Short Selling – Explanation For Shorting Stocks

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply